Clinical Trial Update: A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Cadonilimab (AK104) in combination with Lenvatinib for previously immunotherapy-treated, advanced or metastatic clear cell renal cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Cadonilimab (AK104) (Cadonilimab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: RenJi Hospital | Conditions: Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy | Phase 2 | Status: RECRUITING